KMT5B

Across TCGA pan-cancer cohorts, KMT5B Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated KMT5B data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher KMT5B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KMT5B expression acts as an unfavorable survival marker.

THYM, UCS, and LIHC are the cancer types where KMT5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCS	OS	Median	III,IV	0.104	0.591	.004	24	view →
LIHC	OS	Median	III,IV	0.079	0.737	.004	12	view →
KICH	DFS	Median	II,III,IV	0.102	0.775	.025	3	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
LUAD	OS	Median	II,III,IV	0.227	0.560	.047	3	view →
HNSC	OS	Median	IV	0.506	0.733	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

KMT5B–THYM (OS)

Open the THYM breakdown →